Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2026-04-20 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2026 first extraordinary shareholders' meeting of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and its resolutions. The content focuses on the official disclosure of voting outcomes and meeting decisions rather than the meeting materials or presentations themselves. The document length is short (1225 characters), and it is clearly an announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-20 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司2025年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2025年度持续督导跟踪报告" (2025 Annual Continuous Supervision Follow-up Report) issued by the sponsor institution (财通证券股份有限公司) for 江西新赣江药业股份有限公司. It details the sponsor's ongoing supervision activities, including review of disclosure documents, internal controls, use of raised funds, risk factors, and compliance with regulations. The content is focused on regulatory oversight and compliance monitoring rather than presenting full financial statements or comprehensive annual financial performance. The document length is 3498 characters, which is relatively short and more consistent with a regulatory or supervisory report rather than a full Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or publication notice, nor is it a certification or insider transaction report. The nature of the report aligns with an Audit Report / Information (AR) category, as it involves audit-like supervisory activities and opinions on compliance and internal controls, but is not a full annual report. Therefore, the best classification is AR (Audit Report / Information). FY 2025
2026-04-20 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司2025年度持续督导定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2025年度持续督导定期现场检查报告" which translates to "2025 Annual Continuous Supervision Regular On-site Inspection Report" by a sponsoring securities company regarding a listed company. The content includes detailed on-site inspection items such as corporate governance, internal control, shareholder changes, related party transactions, fundraising usage, and other compliance checks. It is a detailed regulatory compliance and supervisory report rather than a financial statement or earnings release. It does not contain financial statements or earnings highlights but focuses on governance, compliance, and supervisory findings. This fits the definition of an Audit Report / Information (AR) which includes results of internal or regulatory inspections and applied accounting principles, excluding full annual reports. The document length is about 4809 characters, which is sufficient for a substantive report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2025
2026-04-19 Chinese
2025年度独立董事述职报告（石美金）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for the year 2025" from Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the independent director's duties, attendance at board and committee meetings, review of financial reports, audit committee activities, and oversight of governance and compliance matters during the 2025 fiscal year. The content focuses on the independent director's report on their performance and observations rather than the full annual report or audit report itself. It is a formal report by an independent director about their duties and opinions for the year, which is a specific type of governance-related disclosure. This fits best under Board/Management Information (MANG) as it relates to board-level reporting and management oversight, rather than a full Annual Report (10-K), Audit Report (AR), or other categories. The document length (6311 characters) and detailed content support this classification with high confidence.
2026-04-14 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司2025年度募集资金存放及使用情况的专项核查报告
Regulatory Filings
2026-04-14 Chinese
第三届董事会第十九次会议决议公告
Board/Management Information Classification · 90% confidence The document is titled “第三届董事会第十九次会议决议公告” and details the convening of a board meeting, attendance, resolutions considered, votes cast, and follow-up actions. It is a corporate announcement of board meeting resolutions rather than a full financial report, earnings release, or other filings. This matches the “Board/Management Information (MANG)” category for announcements from the board of directors.
2026-04-14 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.